Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Verve Therapeutics, Inc. (VERV : NSDQ)

• Company Description    Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's lead product candidate includes VERVE-101. Verve Therapeutics is based in CAMBRIDGE, Mass. Number of Employees: 274

• Price / Volume Information    Yesterday's Closing Price: $11.06 Daily Weekly Monthly 20 Day Moving Average: 7,535,935 shares Shares Outstanding: 89.14 (millions) Market Capitalization: $985.92 (millions) Beta: 2.23 52 Week High: $11.41 52 Week Low: $2.86 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 75.00% 68.45% 12 Week 140.96% 102.68% Year To Date 96.10% 83.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 BROOKLINE AVENUE SUITE 601 - BOSTON,MA 02215 USA ph: 617-603-0070 fax: - jrobinson@vervetx.com http://www.vervetx.com

• General Corporate Information    Officers Sekar Kathiresan - Chief Executive Officer Allison Dorval - Chief Financial Officer Burt Adelman - Director Lonnel Coats - Director Alexander Cumbo - Director Peer Information Verve Therapeutics, Inc. (GSAC) Verve Therapeutics, Inc. (CASI) Verve Therapeutics, Inc. (ALCD.) Verve Therapeutics, Inc. (OMNN) Verve Therapeutics, Inc. (CGPI.) Verve Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 92539P101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 89.14 Most Recent Split Date: (:1) Beta: 2.23 Market Capitalization: $985.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.71 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.08 Price/Cash Flow: - Price / Sales: 16.54 EPS Growth vs. Year Ago Period: 40.68% vs. Previous Quarter: 39.66% Sales Growth vs. Year Ago Period: 479.03% vs. Previous Quarter: 152.11% ROE 06/30/25 - - 03/31/25 - -35.81 12/31/24 - -37.30 ROA 06/30/25 - - 03/31/25 - -27.57 12/31/24 - -28.96 Current Ratio 06/30/25 - - 03/31/25 - 9.84 12/31/24 - 12.65 Quick Ratio 06/30/25 - - 03/31/25 - 9.84 12/31/24 - 12.65 Operating Margin 06/30/25 - - 03/31/25 - -303.64 12/31/24 - -614.59 Net Margin 06/30/25 - - 03/31/25 - -303.64 12/31/24 - -614.59 Pre-Tax Margin 06/30/25 - - 03/31/25 - -303.10 12/31/24 - -613.51 Book Value 06/30/25 - - 03/31/25 - 5.31 12/31/24 - 5.83 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©